Substantiating this hypothesis, we observed a substantial reduction in tumor volumes upon the prophylactic administration of MC38-424i TEVs to mice subjected to CT26 tumor challenges (Figures 2A and 2C). This evidence concerns the gene DDX53 and neoplasm.